Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV

Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV

Respiratory syncytial virus (RSV) is one of the leading causes of lower respiratory tract infection in infants. Immunoprophylaxis with the anti-RSV monoclonal antibody, palivizumab, reduces the risk for RSV-related hospitalizations, but its use is restricted to high-risk infants due to the high cost...

Full description

Bibliographic Details
Main Authors: Rika Gomi, Anurag Sharma, Wenzhu Wu, Stefan Worgall
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Vaccines
Subjects:
respiratory syncytial virus (RSV)
immunoprophylaxis
palivizumab
chimpanzee adenovirus type 7 (AdC7)
neonate
passive immunization
genetic gene delivery
Online Access:http://www.mdpi.com/2076-393X/7/1/3

Internet

http://www.mdpi.com/2076-393X/7/1/3

Similar Items